Pharmacyclics Company Profile (NASDAQ:PCYC)

About Pharmacyclics

Pharmacyclics logoPharmacyclics, Inc. is an integrated biopharmaceutical company engaged in developing and commercializing therapies for the treatment of cancer and immune-mediated diseases. The Company's commercial product is IMBRUVICA (ibrutinib), which is an oral, single-agent therapy indicated for the treatment of blood cancer. The Company markets IMBRUVICA in the United States for four United States. Food and Drug Administration (FDA) approved indications for the treatment of patients with chronic lymphocytic leukemia (CLL) who have received at least one prior therapy; all lines of CLL with deletion of the short arm of chromosome 17 (del 17p CLL); mantle cell lymphoma (MCL) who have received at least one prior therapy, and all lines of Waldenstrom's macroglobulinemia (WM). It is also pursuing the development of IMBRUVICA for Graft versus host disease (GvHD). In addition, it has a pre-clinical testing program underway to develop inhibitors of BTK for inflammatory and autoimmune diseases.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: PCYC
  • CUSIP: 71693310
Key Metrics:
  • Previous Close: $0.00
  • 50 Day Moving Average: $256.91
  • 200 Day Moving Average: $195.29
  • 52-Week Range: $85.50 - $261.68
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: 48.97
  • P/E Growth: 0.00
  • Market Cap: $N/A
Additional Links:
Companies Related to Pharmacyclics:

Analyst Ratings

Consensus Ratings for Pharmacyclics (NASDAQ:PCYC) (?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for Pharmacyclics (NASDAQ:PCYC)
DateFirmActionRatingPrice TargetDetails
5/29/2015BTIG ResearchReiterated RatingNeutralView Rating Details
4/20/2015BMO Capital MarketsReiterated RatingPositiveView Rating Details
3/6/2015Credit Suisse Group AGReiterated RatingNeutralView Rating Details
3/6/2015Leerink SwannDowngradeOutperform -> Market PerformView Rating Details
3/6/2015WallachBeth CapitalBoost Price TargetHold$222.00 -> $261.00View Rating Details
3/5/2015Piper Jaffray Cos.Set Price TargetHold$184.00View Rating Details
3/5/2015NomuraDowngradeBuy -> Neutral$196.00 -> $261.25View Rating Details
3/5/2015Wells Fargo & Co.DowngradeOutperform -> Market Perform$261.25View Rating Details
3/5/2015Royal Bank Of CanadaBoost Price TargetSector Perform$145.00 -> $261.00View Rating Details
3/3/2015WedbushDowngradeOutperform -> Neutral$225.00 -> $234.00View Rating Details
2/27/2015Goldman Sachs Group Inc.DowngradeHold$184.00View Rating Details
2/26/2015Robert W. BairdBoost Price Target$240.00View Rating Details
2/25/2015Deutsche Bank AGDowngradeBuy -> Hold$235.00View Rating Details
2/19/2015Stifel NicolausReiterated RatingHoldView Rating Details
2/19/2015JPMorgan Chase & Co.DowngradeOverweight -> Neutral$152.00 -> $173.00View Rating Details
2/19/2015Roth CapitalDowngradeBuy -> Neutral$189.00 -> $187.00View Rating Details
1/14/2015Citigroup Inc.Boost Price TargetBuy$145.00 -> $155.00View Rating Details
11/5/2014JMP SecuritiesReiterated RatingMarket Outperform$200.00 -> $204.00View Rating Details
11/5/2014Morgan StanleyReiterated RatingEqual Weight$103.00 -> $111.00View Rating Details
(Data available from 10/26/2014 forward)


Earnings History for Pharmacyclics (NASDAQ:PCYC)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/1/2015Q115$0.11$0.13$226.27 million$206.00 millionViewN/AView Earnings Details
2/18/2015Q414$0.76$0.96$267.50 million$290.00 millionViewN/AView Earnings Details
11/4/2014Q314$0.37$0.69$201.50 million$207.10 millionViewN/AView Earnings Details
7/31/2014Q214($0.23)($0.26)$95.88 million$113.00 millionViewN/AView Earnings Details
5/2/2014Q114$0.17$0.40$105.38 million$119.40 millionViewN/AView Earnings Details
2/20/2014Q413$0.67$0.95$85.69 million$123.60 millionViewN/AView Earnings Details
7/31/2013Q2 2013($0.07)$0.26$52.00 million$54.70 millionViewN/AView Earnings Details
5/1/2013Q3 2013($0.03)($0.40)$2.84 millionViewN/AView Earnings Details
2/14/2013Q2 2013$0.29$0.62$45.74 million$57.96 millionViewN/AView Earnings Details
11/5/2012Q113$0.75$1.14$87.64 million$102.70 millionViewN/AView Earnings Details
9/5/2012Q412($0.27)($0.22)$3.49 million$2.10 millionViewN/AView Earnings Details
5/10/2012($0.20)($0.14)ViewN/AView Earnings Details
2/9/2012($0.18)$0.82ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Pharmacyclics (NASDAQ:PCYC)
Current Year EPS Consensus Estimate: $0.73 EPS
Next Year EPS Consensus Estimate: $5.25 EPS


Dividend History for Pharmacyclics (NASDAQ:PCYC)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for Pharmacyclics (NASDAQ:PCYC)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
3/13/2015Manmeet Singh SoniCFOSell27,514$254.24$6,995,159.36View SEC Filing  
3/12/2015Heow TanInsiderSell1,000$254.51$254,510.00View SEC Filing  
11/12/2014Maky ZanganehCOOSell30,482$134.69$4,105,620.58View SEC Filing  
11/10/2014Maky ZanganehCOOSell23,000$133.83$3,078,090.00View SEC Filing  
11/10/2014Richard B LoveGeneral CounselSell1,500$133.87$200,805.00View SEC Filing  
11/7/2014Maky ZanganehCOOSell1,551$135.01$209,400.51View SEC Filing  
11/7/2014Maria FardisInsiderSell5,000$134.50$672,500.00View SEC Filing  
9/4/2014Maky ZanganehCOOSell12,000$121.75$1,461,000.00View SEC Filing  
8/27/2014Richard B LoveGeneral CounselSell1,500$124.00$186,000.00View SEC Filing  
8/13/2014Heow TanInsiderSell10,000$123.58$1,235,800.00View SEC Filing  
8/7/2014Jesse McgreivyInsiderSell34,062$120.92$4,118,777.04View SEC Filing  
3/5/2014Boultbee Paula SjovallEVPSell20,000$138.22$2,764,400.00View SEC Filing  
3/5/2014Gregory HemmiVPSell15,000$140.00$2,100,000.00View SEC Filing  
3/5/2014Jesse McgreivyInsiderSell6,563$139.66$916,588.58View SEC Filing  
3/4/2014Betty ChangVPSell17,500$137.97$2,414,475.00View SEC Filing  
2/27/2014Den Broek Richard VanDirectorSell78,835$146.63$11,559,576.05View SEC Filing  
12/19/2013Heow TanInsiderSell5,000$100.87$504,350.00View SEC Filing  
12/18/2013Gregory HemmiVPSell20,000$100.52$2,010,400.00View SEC Filing  
12/16/2013Rainer ErdtmannVPSell54,000$107.77$5,819,580.00View SEC Filing  
6/6/2013Scott T ShearerVPSell18,750$85.17$1,596,937.50View SEC Filing  
5/31/2013Heow TanInsiderSell5,237$91.84$480,966.08View SEC Filing  
5/31/2013Jesse McgreivyVPSell14,479$91.13$1,319,471.27View SEC Filing  
2/5/2013David J LouryInsiderSell20,000$70.58$1,411,600.00View SEC Filing  
12/28/2012Den Broek Richard VanDirectorSell30,285$57.99$1,756,227.15View SEC Filing  
12/27/2012Gregory HemmiVPSell13,000$59.20$769,600.00View SEC Filing  
(Data available from 1/1/2013 forward)


Latest Headlines for Pharmacyclics (NASDAQ:PCYC)
News IconWhy ACADIA Pharmaceuticals Inc (ACAD) Stock Loss Will Reverse With Nuplazid Sales, Eventually! - BNL Finance (press release) (registration) (blog) (NASDAQ:PCYC) - October 25 at 6:46 PM
News IconACADIA Pharmaceuticals Inc: ACAD Stock Owners Must See This Chart! - BNL Finance (press release) (registration) (blog) (NASDAQ:PCYC) - October 14 at 6:28 PM
News IconPharmacyclics, Inc. (NASDAQ:PCYC) Updated Broker Price Targets - The De Soto Edge (NASDAQ:PCYC) - September 29 at 6:38 PM logoAbbVie : Announces Submission of a Supplemental New Drug Application for Ibrutinib (IMBRUVICA®) for Treatment of Marginal Zone Lymphoma (NASDAQ:PCYC) - September 27 at 6:34 PM
News IconActive Eye Catching Stocks- AbbVie (NYSE:ABBV), Pain Therapeutics (NASDAQ:PTIE), Lands' End (NASDAQ:LE) - Seneca Globe (NASDAQ:PCYC) - September 27 at 11:19 AM
News IconAbbVie (ABBV) Files sNDA for Blood Cancer Drug Imbruvica - Yahoo News (NASDAQ:PCYC) - September 27 at 11:19 AM
News IconeBay Inc (NASDAQ:EBAY) & AbbVie Inc (NYSE:ABBV) Traders Alert - Money News (NASDAQ:PCYC) - September 27 at 11:19 AM logoAbbVie Announces Submission of a Supplemental New Drug Application for Ibrutinib (IMBRUVICA®) for Treatment of Marginal Zone Lymphoma (NASDAQ:PCYC) - September 26 at 6:47 PM logoAbbVie Announces Submission of a Supplemental New Drug Application for Ibrutinib (IMBRUVICA®) for - PR Newswire (press release) (NASDAQ:PCYC) - September 26 at 11:30 AM logoSeveral Companies Reach 52-Week Highs - Yahoo Finance (NASDAQ:PCYC) - September 21 at 6:19 PM logoSeveral Companies Reach 52-Week Highs (NASDAQ:PCYC) - September 20 at 11:58 AM
News IconMy "Early Warning" System for Maximum Tech Profits - Money Morning (NASDAQ:PCYC) - August 29 at 6:30 PM logoGoldman Sachs Talks Pfizer's Acquisition Deal Of Medivation - Benzinga (NASDAQ:PCYC) - August 24 at 9:50 AM
News IconJanssen receives Health Canada approval for Imbruvica to treat chronic lymphocytic leukaemia - (NASDAQ:PCYC) - July 23 at 6:15 PM
News IconHealth Canada Approves IMBRUVICA® (ibrutinib) for First-line Treatment of Chronic Lymphocytic Leukemia - Edmonton Journal (NASDAQ:PCYC) - July 20 at 9:38 AM logoNew Broker Ratings For Pharmacyclics, Inc. (NASDAQ:PCYC) - FTSE News (NASDAQ:PCYC) - July 18 at 6:53 PM
News IconPharmacyclics' Leukemia Drug Scores over Glaxo's in Head-to-Head Trial - The Westside Story (NASDAQ:PCYC) - June 27 at 6:45 PM logoRecently Issued Stock Ratings For Pharmacyclics, Inc. (NASDAQ:PCYC) - Fiscal Standard (NASDAQ:PCYC) - June 23 at 7:18 PM logoAnalyst Views For The Week Ahead: Pharmacyclics, Inc. (NASDAQ:PCYC) - Fiscal Standard (NASDAQ:PCYC) - June 20 at 8:21 AM
News IconHere's How Julius Caesar Would've Reacted to This Biotech Foul-Up - Money Morning (NASDAQ:PCYC) - June 7 at 6:57 PM
News IconDrug-Makers Once Again Win Street Race- AbbVie Inc. (NYSE:ABBV), Pfizer Inc. (NYSE:PFE) - Seneca Globe (NASDAQ:PCYC) - June 7 at 6:57 PM logoACADIA Pharmaceuticals Could Be Acquired - Seeking Alpha (NASDAQ:PCYC) - June 7 at 9:30 AM logoAbbVie (ABBV) Announces Additional Data on IMBRUVICA Phase 3 in CLL/SLL - (NASDAQ:PCYC) - June 6 at 10:26 AM
News IconAfter Last Week What Do Analysts Think Of Pharmacyclics, Inc. (NASDAQ:PCYC) - Share Trading News (NASDAQ:PCYC) - June 6 at 10:26 AM logoAbbVie (ABBV) Receives EC Approval of IMBRUVICA as CLL Treatment - (NASDAQ:PCYC) - May 31 at 7:01 PM logoEuropean Commission Approves IMBRUVICA® (ibrutinib) for First-Line Treatment of Patients with Chronic Lymphocytic ... - PR Newswire (press release) (NASDAQ:PCYC) - May 31 at 6:38 AM
News IconAbbVie Announces FDA Expands Label for Imbruvica - Drug Discovery & Development (NASDAQ:PCYC) - May 16 at 10:11 AM logoMedivation Is for Sale: How Much Should It Get? (NASDAQ:PCYC) - May 13 at 6:07 PM logoWhy June Could Be a Big Month for AbbVie Investors (NASDAQ:PCYC) - May 12 at 4:40 PM
News IconComprehensive Analysis of: AbbVie Inc (NYSE:ABBV) - News Oracle (NASDAQ:PCYC) - May 11 at 5:41 PM logoWhere AbbVie Inc (NYSE:ABBV) Stands on Analytical Review Chart? - The Point Review (NASDAQ:PCYC) - May 11 at 5:41 PM
News IconU.S. FDA Expands IMBRUVICA Label To Include Overall Survival Data (NASDAQ:PCYC) - May 11 at 3:46 AM logoAbbVie (ABBV) Announces FDA Update to IMBRUVICA Prescribing Info; Incldues Phase 3 Data for CLL - (NASDAQ:PCYC) - May 9 at 5:29 PM
News IconNext Weeks Broker Price Targets For Pharmacyclics, Inc. (NASDAQ:PCYC) - Share Trading News (NASDAQ:PCYC) - May 8 at 5:36 PM
News IconEMA recommends expanded indication of Janssen's Imbruvica in previously untreated CLL - (NASDAQ:PCYC) - May 2 at 5:51 PM logoTax Savvy Execs Work For $1, Get Paid Millions As Capital Gain (NASDAQ:PCYC) - May 2 at 8:43 AM logoJanssen-Cilag Receives Positive CHMP for IMBRUVICA in Previously Untreated CLL - (NASDAQ:PCYC) - April 29 at 5:47 PM
News IconPharmacyclics, Inc. (NASDAQ:PCYC) Updated Broker Price Targets - Share Trading News (NASDAQ:PCYC) - April 28 at 10:56 PM
News IconBroker Outlook For Pharmacyclics, Inc. (NASDAQ:PCYC) - Share Trading News (NASDAQ:PCYC) - April 19 at 5:55 PM
News IconMedivation Stock Up After Rumors It Rejected Sanofi Acquisition Bid - PharmaLive (press release) (subscription) (NASDAQ:PCYC) - April 13 at 10:51 PM
News IconUpgrades And Downgrades For Pharmacyclics, Inc. (NASDAQ:PCYC) - Risers & Fallers (NASDAQ:PCYC) - April 12 at 10:51 PM
News IconPharmacyclics, Inc. (NASDAQ:PCYC) Broker Price Targets For The Coming Week - Share Trading News (NASDAQ:PCYC) - April 3 at 5:12 PM
News IconAriad Cuts Another 25% of Workforce at HQ - PharmaLive (press release) (subscription) (NASDAQ:PCYC) - March 31 at 10:35 PM
News IconPharmacyclics, Inc. (NASDAQ:PCYC): Analyst Targets For The Coming Week - Share Trading News (NASDAQ:PCYC) - March 22 at 10:28 PM
News IconPharmacyclics, Inc. (NASDAQ:PCYC) Recent Analyst Updates - Risers & Fallers (NASDAQ:PCYC) - March 22 at 10:01 AM
News IconPharmacyclics, Inc. (NASDAQ:PCYC) New Analyst Ratings - Share Trading News (NASDAQ:PCYC) - March 18 at 5:41 PM logoEarnings Outlook For Pharmacyclics, Inc. (NASDAQ:PCYC) - Investor Newswire (NASDAQ:PCYC) - March 15 at 5:36 PM
News IconChanges To Broker Targets On Pharmacyclics, Inc. (NASDAQ:PCYC) - Share Trading News (NASDAQ:PCYC) - March 10 at 5:20 PM
News IconFDA Approves Imbruvica for First-Line Treatment of CLL - Drug Discovery & Development (NASDAQ:PCYC) - March 7 at 5:28 PM logoJim Cramer -- Here's Why I'm Buy, Buy, Buying J&J and Selling Merck (NASDAQ:PCYC) - May 26 at 2:27 PM


Pharmacyclics (NASDAQ:PCYC) Chart for Wednesday, October, 26, 2016

Last Updated on 10/26/2016 by Staff